Business Wire

FONDATION-IPSEN

19.11.2016 16:21:30 CET | Business Wire | Press release

Share
The 21st Longevity Prize of the Fondation Ipsen will be awarded to Kaare Christensen

The Fondation IPSEN Longevity Prize will be given this year at the GSA meeting (Gerontological Society of America), in New Orleans on November 19th, 2016. The international jury chaired by Professor Thomas Kirkwood (Newcastle University, UK and Copenhagen University, Denmark), have unanimously decided to award the prize to Kaare Christensen for his pioneering work on the importance of genes and environment in aging and longevity.

Kaare Christensen, MD, PhD, DRMSC, is Professor of Epidemiology at the University of Southern Denmark and Senior Research Scientist at the Terry Sanford Institute, Duke University, North Carolina, USA. Dr. Christensen is the Director of the Danish Twin Registry and the Danish Aging Research Center. He has conducted a long series of studies among twins and the oldest-old in order to shed light on the importance of genes and environment in aging and longevity. Furthermore, he has a longstanding interest in the relation between early life events and later life health outcome.

Abstract of his lecture: “Is Mortality written on the face? Or Elsewhere?”

Predicting length of life is of interest to individuals, medical doctors, demographers and researchers on aging. While most people would probably be uncomfortable with an exact prediction at an individual level (if that were possible), the identification of factors associated with health and survival can potentially provide the basis for decision making, interventions and public health initiatives. A series of “the usual suspects” is known to be associated with health and survival, e.g. birth cohort, gender, smoking and other life style factors, genetics, early life and socioeconomic factors. Over the last decades, this list has been extended with biomarkers of aging that include performance measures and molecular markers such as leukocyte telomere length and DNA methylation age. We have used nationwide cohort studies of twins, oldest-old individuals and long-lived families in Denmark to understand variance in health and survival and to identify clinically useful biomarkers of aging. Perhaps surprisingly, we have found that among the elderly, simple, low-tech biomarkers, including perceived age based on photos, are among the most powerful indicators of aging.

The Longevity Prize

Created in 1996, this Prize of the Fondation Ipsen has been awarded every year to renowned specialists in Longevity:

Caleb E. Finch (University of Southern California, Los Angeles, USA), Vaïno Kannisto (Odense University, Denmark) , Roy L. Walford (formerly University of California Los Angeles, USA), John E. Morley (St. Louis University, USA), Paul B. and Margret M. Baltes (formerly Free University of Berlin, Germany), Justin D. Congdon (University of Georgia, Aiken, USA), George M. Martin (University of Washington, Seattle, USA), James W. Vaupel (Max-Planck Institute for Demographic Research, Rostock, Germany), Linda Partridge (University College London, UK), Sir Michael Marmot (University College London, UK), Cynthia Kenyon (University of California, San Francisco, USA), David J.P. Barker (University of Southampton, UK), Gerald McClearn (Pennsylvania State University, University Park, USA), Jacques Vallin (French National Institute of Demography, Paris, France), Judith Campisi (Buck Institute for Age Research, Novato, USA), Thomas Kirkwood (Newcastle University, Newcastle upon Tyne, UK), Linda Fried (Columbia University, New York, USA), Gary Ruvkun (Harvard Medical School - CCIB, Boston, US), Luigi Ferrucci (National Institute on Aging, NIH, Baltimore, USA) and Steven N. Austad (University of Alabama at Birmingham, USA).

Members of the jury

Thomas Kirkwood, President (Newcastle University, UK Copenhagen University, Denmark), Judith Campisi (Buck Institute for Research on Aging, Novato, USA), Eileen Crimmins (University of Southern California, Los Angeles, USA), Caleb Finch (University of Southern California, Los Angeles, USA), Bernard Jeune* (University of Southern Denmark, Odense, Denmark), George Martin* (University of Washington, Seattle, USA), Yasuyuki Gondo (Osaka University, Japan), Jean-Marie Robine (INSERM, Démographie et Santé, Montpellier, France), Bruno Vellas (University of Toulouse, France), Marja Jylhä (University of Tampere, Finland), Steven N. Austad (University of Alabama at Birmingham, USA), Luigi Ferrucci (National Institute on Aging, Baltimore, USA) and a Fondation IPSEN representative.

(* Former Jury Members).

The Fondation IPSEN

Established in 1983 under the aegis of the Fondation de France, the ambition of the Fondation IPSEN is to initiate a reflection about the major scientific issues of the forthcoming years. The long-standing mission of the Fondation IPSEN is to contribute to the development and dissemination of scientific knowledge by fostering interaction between scientists and clinicians. It has developed an important international network of scientific experts who meet regularly at meetings known as Colloques Médecine et Recherche, dedicated to three main topics: neurosciences, endocrinology and cancer science. Moreover the Fondation IPSEN has started several series of meetings in partnership with the Salk Institute, the Karolinska Institute as well as with the science journals Cell and Science. The Fondation IPSEN produced several hundred publications and more than 250 scientists have been awarded prizes and grants.

www.fondation-ipsen.org

Contact:

Image Sept
Isabelle de Segonzac, +33 (0)1 53 70 74 70
isegonzac@image7.fr

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

VDYNE Receives FDA Approval to Initiate the TRIVITA1 IDE Pivotal Trial of Transcatheter Tricuspid Valve Replacement System1.4.2026 15:30:00 CEST | Press release

VDYNE, Inc. (“VDYNE” or “the Company”), a privately held medical device company developing next generation transcatheter valve replacement technologies, today announced that the U.S. Food & Drug Administration (FDA) has approved an investigational device exemption (IDE) for the company’s pivotal clinical trial evaluating its Transcatheter Tricuspid Valve Replacement (TTVR) system. The IDE approval enables initiation of a U.S. pivotal study at leading clinical centers to evaluate the safety and effectiveness of the VDYNE system in patients with severe tricuspid regurgitation (TR). “This is a defining milestone for VDYNE and an important step toward bringing a much-needed therapy to patients with severe tricuspid regurgitation,” said Mike Buck, Chief Executive Officer. “Our focus now is on disciplined clinical execution and partnering with leading investigators to generate high-quality data that advances the field and improves patient care.” Significant unmet clinical needs exist in the

NetJets Introduces State-of-the-Art, Exclusive-Use Terminal in Augusta, Georgia1.4.2026 15:05:00 CEST | Press release

New facility set to elevate the experience for customers during golf’s most celebrated event—and beyond NetJets, the global leader in private aviation, is well underway on its development of a new exclusive-use terminal at Augusta Regional Airport (AGS). This state-of-the-art facility represents a significant investment in the region and reinforces NetJets’ commitment to delivering unparalleled experiences for its customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330125414/en/ NetJets to open a new, exclusive-use terminal at Augusta Regional Airport (AGS). Guests arriving this April for golf’s most iconic championship will witness the construction in progress, including the finished ramp and foundational walls of what will soon become a full-service terminal. The private ramp, offering 432,000 square feet of space for aircraft parking, will be completed in time for the 2026 golf tournament. “Augusta is a key desti

Visa Unveils New Services to Modernize Dispute Resolution Process1.4.2026 15:00:00 CEST | Press release

Fraudulent disputes and administrative inefficiencies drive billions in avoidable economic costsSix new and enhanced dispute resolution tools utilize AI and proprietary technology to help provide issuers, acquirers and merchants with increased visibility into costly fraud expenses Visa (NYSE: V), a global leader in digital payments, today announced six new dispute resolution tools designed to reduce the billions of dollars lost annually to inefficient, outdated dispute processes. The expanded suite of dispute resolution services is being designed to help merchants and financial institutions cut administrative costs, reduce fraud-related losses and redirect those resources toward growth, innovation and customer experience. Disputes remain one of the most persistent friction points in commerce, driving rising costs for merchants and financial institutions while simultaneously leaving consumers frustrated and confused. In 2025, Visa processed 106 million disputes globally, a 35% increase

Rimini Street Announces Debt Reduction and Amendment to its Credit Agreement1.4.2026 15:00:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced first quarter debt reduction activities and a recent amendment to its credit agreement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401160360/en/ Rimini Street Announces Debt Reduction and Amendment to its Credit Agreement Debt reduction activities during the first quarter of 2026 totaled $10.9 million, reducing the Company’s outstanding term loan to $58.4 million as of March 31, 2026. The Company’s credit agreement was amended effective as of March 27, 2026 to increase to $20.0 million the value of Company common stock that could be repurchased per annum, beginning with the Company’s 2026 fiscal year and for each fiscal year thereafter, with a revised total of $50.0 million in permitted stock repurchases from the period beginning January

Neuphonic and Rapport Bring Real-Time Digital Humans to Everyday Hardware1.4.2026 15:00:00 CEST | Press release

New partnership delivers sub-100ms, fully on-device avatars — unlocking scalable, lifelike AI characters for games, film and interactive media Neuphonic and Rapport (a division of Speech Graphics) today announced a partnership to deliver what they believe is among the first fully real-time, photorealistic digital human systems running entirely on standard CPU hardware. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401782320/en/ Rapport and Neuphonic announce a partnership to deliver next-generation conversational AI experiences. The collaboration combines Neuphonic’s ultra-low latency text-to-speech technology with Rapport, an interactive AI avatar role play platform powered by production-proven real-time facial and full-body animation technology from Speech Graphics, used in video games such as Call of Duty, The Last of Us Part II and Hogwarts Legacy. Together, the system generates natural voice, perfectly synchronised

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye